

Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study

Di Qi*, Xiaofeng Yan*, Xumao Tang*, Junnan Peng, Qian Yu, Longhua Feng, Guodan Yuan, An Zhang, Yaokai Chen, Jing Yuan, Xia Huang, Xianxiang Zhang, Peng Hu, Yuyan Song, Chunfang Qian, Qiangzhong Sun, Daoxin Wang†, Jin Tong†, Jianglin Xiang†

*Joint first authors †Joint corresponding authors

Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (D Qi, X Tang, J Peng, Q Yu, D Wang, J Tong); Chongqing Public Health Medical Center, Chongqing, China(X Yan); Qianjiang Central Hospital of Chongqing, Chongqing, China(L Feng); Department of Intensive Care Medicine, Chongqing Public Health Medical Center, Chongqing, China(G Yuan, Y Song); Department of Intensive Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China(A Zhang); Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China(Y Chen, J Yuan); Department of Infectious Diseases, Chongqing Three Gorges Central Hospital, Chongqing, China(X Huang, J Xiang); Department of Infectious Diseases, Chongqing University Three Gorges Hospital, Chongqing, China(X Huang, J Xiang); Chongqing University Three Gorges Hospital, Chongqing, China(X Zhang); Chongqing Three Gorges Central Hospital, Chongqing, China(X Zhang); Department of Infectious Diseases, Institute for Viral Hepatitis, the Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China(P Hu); Department of Tuberculosis Diseases, Chongqing Public Health Medical Center, Chongqing, China(C Qian, Q Sun).

Correspondence to:

1. Prof Daoxin Wang, Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

wangdaoxin1@163.com

2. Prof Jin Tong, Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

tongjin01234@163.com

3. Prof Jianglin Xiang, Department of Infectious Diseases, Chongqing Three Gorges Central Hospital, Chongqing, China; Department of Infectious Diseases, Chongqing University Three Gorges Hospital, Chongqing, China

1448026879@qq.com

Conflict of interest statements

The authors declare no conflict of interest.

Abstract:

Background

In January 19, 2020, first case of 2019 novel coronavirus (2019-nCoV) pneumonia (COVID-19) was confirmed in Chongqing municipality, China.

Methods

In this retrospective, descriptive, multiple-center study, total of 267 patients with COVID-19 confirmed by real-time RT-PCR in Chongqing from Jan 19 to Feb 16, 2020 were recruited. Epidemiological, demographic, clinical, radiological characteristics, laboratory examinations, and treatment regimens were collected on admission. Clinical outcomes were followed up until Feb 16, 2020.

Results

267 laboratory-confirmed COVID-19 patients admitted to 3 designated-hospitals in Chongqing provincial municipality from January 19 to February 16, 2020 were enrolled and categorized on admission. 217 (81.27%) and 50 (18.73%) patients were categorized into non-severe and severe subgroups, respectively. The median age of patients was 48.0 years (IQR, 35.0-65.0), with 129 (48.3%) of the patients were more than 50 years of age. 149 (55.8%) patients were men. Severe patients were significantly older (median age, 71.5 years [IQR, 65.8-77.0] *vs* 43.0 years [IQR, 32.5-57.0]) and more likely to be male (110 [50.7%] *vs* 39 [78.0%]) and have coexisting disorders (15 [30.0%] *vs* 26 [12.0%]). 41 (15.4%) patients had a recent travel to Hubei province, and 139 (52.1%) patients had a history of contact with patients from Hubei. On admission, the most common symptoms of COVID-19 were fever 225(84.3%), fatigue (208 [77.9%]), dry cough (189 [70.8%]), myalgia or arthralgia (136 [50.9%]). Severe patients were more likely to present dyspnea (17 [34.0%] *vs* 26 [12.0%]) and confusion (10 [20.0%] *vs* 15 [6.9%]). Rales (32 [12.0%]) and wheezes (20 [7.5%]) are not common noted for COVID-19 patients, especially for the non-severe (11 [5.1%], 10 [4.6%]). 118 (44.2%). Most severe patients demonstrated more laboratory abnormalities. 231 (86.5%), 61 (22.8%) patients had lymphopenia, leukopenia and thrombocytopenia, respectively. CD4⁺T cell counts decrease was observed in 77.1 % of cases, especially in the severe patients (45, 100%).

53.1% patients had decreased CD⁺3 T cell counts, count of CD8⁺T cells was lower than the normal range in part of patients (34.4%). More severe patients had lower level of CD4⁺ T cells and CD⁺3 T cells (45 [100.0%] vs 29[56.9%], 31 [68.9%] vs 20 [39.2%]). Most patients had normal level of IL-2, IL-4, TNF- α and INF- γ , while high level of IL-6 and IL-17A was common in COVID-19 patients (47 [70.1%], 35 [52.2%]). Level of IL-6, IL-17A and TNF- α was remarkably elevated in severe patients (32 [84.2%] vs 15 [51.7%], 25 [65.8%] vs 10 [34.5%], 17 [44.7%] vs 5 [17.2%]). All patients received antiviral therapy (267, 100%). A portion of severe patients (38, 76.0%) received systemic corticosteroid therapy. Invasive mechanical ventilation in prone position, non-invasive mechanical ventilation, high-flow nasal cannula oxygen therapy was adopted only in severe patients with respiratory failure (5[10.0%], 35[70.0%], 12[24.0%]). Traditional Chinese medicine was adopted to most of severe patients (43,86.0%).

Conclusion:

Our study firstly demonstrated the regional disparity of COVID-19 in Chongqing municipality and further thoroughly compared the differences between severe and non-severe patients. The 28-day mortality of COVID-19 patients from 3 designed hospitals of Chongqing is 1.5%, lower than that of Hubei province and mainland China including Hubei province. However, the 28-mortality of severe patients was relatively high, with much higher when complications occurred. Notably, the 28-mortality of critically severe patients complicated with severe ARDS is considerably as high as 44.4%. Therefore, early diagnosis and intensive care of critically severe COVID-19 cases, especially those combined with ARDS, will be considerably essential to reduce mortality.

Keywords:

Coronavirus; Novel coronavirus (2019-nCoV); COVID-19; Chongqing; Clinical characteristics

Introduction:

Since December of 2019, a cluster of cases of pneumonia with unknown etiology

occurred in Wuhan, Hubei Province, China¹. A novel coronavirus named the 2019 novel coronavirus (2019-nCoV) was soon isolated on January 12, 2020 and identified as the causative pathogen of this pneumonia². On February 21, 2020, National Health Commission of the republic of China re-named this 2019-nCoV-infected pneumonia as 2019-nCoV acute respiratory disease (COVID-19). Person-to-person transmission of COVID-19 in hospital and family settings is reported to be accumulating³. As of February 16, 2020, there are 70548 laboratory-confirmed cases and 1770 death cases in China, including 551 confirmed cases in Chongqing. The first laboratory-confirmed case of COVID-19 in the Chongqing municipality is reported on January 19, 2020.

Coronaviruses (CoV) are enveloped non-segmented positive-sense RNA viruses belonging to the family Coronaviridae, which can be transmitted between animals and humans. The 2019-nCoV is the seventh member of enveloped RNA coronavirus². Coronavirus infections cause illness ranging from the mild cold to severe respiratory diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV), with mortality rates of 10% for SARS-CoV and 37% for MERS-CoV⁴. So far, a few patients of COVID-19 have developed severe pneumonia, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS) and had died⁵.

Recently, there are some studies demonstrating the clinical characteristics and epidemiology of COVID-19 patients in Wuhan or throughout China⁵⁻⁸. As Chongqing is reported to be one of the major cities imported passengers from Wuhan in China from December 16, 2019⁹. Given the regional disparity of COVID-19, we aim to describe epidemiological, clinical, laboratory, and radiological features, treatment, and prognosis of COVID-19 patients in Chongqing municipality, and compare the differences between non-severe and severe patients, which may unravel risk factors associated with 28-day mortality and further suggest a specific therapeutic intervention for patients with COVID-19 in Chongqing municipality, China.

Methods:

Study Design and patients

A retrospective, descriptive, multiple-center study on the clinical characteristics of

laboratory-confirmed cases with COVID-19 in Chongqing was performed in accordance with the Declaration of Helsinki. 267 laboratory-confirmed COVID-19 patients admitted to 3 designated-hospitals (Qianjiang central hospital of Chongqing, Chongqing three gorges central hospital and Chongqing public health medical center) in Chongqing provincial municipality from January 19 to February 16, 2020 were enrolled and categorized on admission. Patients with COVID-19 were diagnosed based on the World Health Organization (WHO) interim guidance¹⁰ and categorized into severe and non-severe COVID-19 according to the American Thoracic Society guideline. ARDS was defined according to the Berlin definition¹¹. Informed consent was yielded due to the anonymous analysis of clinical data in retrospective study. This research was approved by the institutional ethics board of the Second Affiliated Hospital of Chongqing Medical University (No.2020-09), Chongqing public health medical center (No.2020-015-01-KY), Chongqing three gorges central hospital (No.2020-13) and Qianjiang central hospital of Chongqing (No.2020-07).

Sample collection

Respiratory specimens, including nasopharyngeal swab and bronchoalveolar lavage fluid (BALF), or anal swab specimens were collected at admission to detect the presence of 2019-nCoV by real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay in designated authoritative laboratories of local centers for disease control and prevention¹². Bacterial, fungal, and pathogenic microorganism test in respiratory and blood samples was routinely performed. Cytokines and lymphocyte subsets in peripheral blood were measured by fluorescence-labeled flow cytometry (Beckman, Cell Lab Quanta SC)

Data Collection

The epidemiological, demographic, clinical, laboratory, radiological, treatment and outcomes data from confirmed COVID-19 patients' medical and nursing records were obtained and analyzed. The date of disease onset was defined as the day when the symptoms were noticed. Clinical outcomes were followed up to February 16, 2020. Data were entered into a computerized database and were checked by two physicians.

Statistical analysis

Continuous variables were expressed as the means and standard deviations (SD) or medians and interquartile ranges (IQR) as appropriate. Categorical variables were presented as the counts and percentages. Independent group t tests were used for comparison of means for continuous variables when the data were normally distributed; otherwise, the Mann-Whitney U test was used. Proportions for categorical variables were compared using the χ^2 test or Fisher exact test. Data analyses were performed using GraphPad Prism 7.0 software and SPSS 19.0 software. A value of $p < 0.05$ was considered statistically significant.

Results

Epidemiology and clinical characteristics

Of all 309 patients enrolled as of February 16, 2020, 42 patients were excluded due to incompleteness of crucial data in original reports. None of medical staff were infected. Hence this study includes 267 patients with COVID-19 from 3 designed-hospitals in Chongqing municipality, China.

The epidemiological and clinical characteristics are shown in Table 1. The median age of the patients was 48.0 years (IQR, 35.0-65.0), with 129 (48.3%) of the patients were more than 50 years of age. 149 (55.8%) patients were men. Most of cases (80.1%) had no smoke history. In our study, only 41 (15.4%) patients had underlying comorbidities including overweight and obesity (30 [11.2%]), diabetes (26 [9.7%]), respiratory system disease diseases (25 [9.4%]), hypertension (20 [7.5%]), cardiovascular and cerebrovascular disease (13 [4.9%]), digestive system disease (12 [4.5%]) and malignant tumor (2 [0.7%]). 41 (15.4%) COVID-19 patients had a recent travel to Wuhan or Hubei province, 139 (52.1%) patients had a history of contact with patients from Wuhan or Hubei, 18 (6.7%) patients had definite contact with the patients infected by confirmed COVID-19 patients from Wuhan or Hubei province. No definite epidemiological link was found in the 69 (25.8%) patients. There is only one patient in our study had definite direct exposure to Huanan seafood market.

On admission, the most common symptoms of COVID-19 were fever 225(84.3%), fatigue (208 [77.9%]), dry cough (189 [70.8%]), myalgia or arthralgia (136 [50.9%]). Less common initial symptoms included nasal congestion (53 [19.9%]), pharyngalgia

(41 [15.4%]), dyspnea (43 [16.1%]), chill (30 [11.2%]), confusion (25 [9.4%]). A portion of patients initially presented with symptoms of digestive system such as anorexia (46 [17.2%]), diarrhea (10 [3.7%]) nausea or vomiting (6 [2.2%]). Abnormal signs of physical examination on admission, including throat congestion (6 [2.2%]), tonsil swelling (3 [1.1%]) and enlargement of lymph nodes (3 [1.1%]), are relatively rare. Notably, for auscultation of abnormal breath sound, rales (32 [12.0%]) and wheezes (20 [7.5%]) are not common noted for COVID-19 patients in Chongqing, especially for the non-severe patients (11 [5.1%], 10 [4.6%]). The median durations from symptoms onset to laboratory diagnosis and hospital admission were 4 days (IQR, 2.0-8.0) and 7 days (IQR, 3.0-10.0) respectively.

Laboratory and radiologic results

The Laboratory and radiologic findings are shown in Table 2. On day of hospital admission, most patients had normal level of leucocytes (134 [50.2%]) and neutrophils (146 [54.7%]) counts, with 118 (44.2%), 231 (86.5%), 61 (22.8%) patients had lymphopenia, leukopenia and thrombocytopenia, respectively. Among the 96 patients underwent for lymphocyte subsets detection, decreases in CD4 positive T cell counts were observed in 77.1 % of cases, especially in the severe patients (45, 100%). More patients (53.1%) had decreased CD positive 3 T cell counts, the level of CD8 positive T cells was lower than the normal range in part of patients (34.4%). The average level of haemoglobin was in normal range (135.0 [95.0-165.0]). Few patients had myocardial zymogram abnormality, which showed elevated level of lactate dehydrogenase (LDH), creatine kinase (CK) and creatine kinase isoenzyme (CKMB) in 21.3%, 18.7% and 12.4% of patients, respectively, which indicates a degree of cardiac injury. Few patients presented mild live function abnormality, with elevated level of alanine aminotransferase (ALT) (20 [7.5%]), aspartate aminotransferase (AST) (19 [7.1%]), total bilirubin (6 [2.2%]), direct bilirubin (7 [2.6%]) or indirect bilirubin (3 [1.1%]). Other dysfunctions in kidney and coagulation were rare, with mild increases of creatinine and D-dimer in 1.5% and 7.1% of patients.

Regarding the infection index, 25.3%, 15.9% and 41.5% of patients had higher level of C-reactive protein (CRP), procalcitonin (PCT) and erythrocyte sedimentation rate (ESR), respectively. Furthermore, there are 67 patients detected for cytokines in peripheral blood. Most patients had normal level of IL-2, IL-4, TNF- α and INF- γ , while high level of IL-6 and IL-17A was common in COVID-19 patients (47 [70.1%], 35 [52.2%]).

Of all patients who underwent radiologic examination (X-ray or CT), most of patients presented as pneumonia with bilateral ground-glass opacity (43.3%) or unilateral ground-glass opacity or patchy shadowing (41.1%), co-existed with consolidation or fibrous stripes-like shadows (5.6%). Pneumothorax or hydrothorax occurred rarely (1 [0.4%], 1 [0.4%]). 36 cases (15.6%) had no obvious radiological abnormality. Additionally, Figure 1-3 demonstrates the representative radiologic images of patients with non-severe and a patient with severe COVID-19 in Chongqing.

Comparison of non-severe and severe patients

On admission, 217 (81.27%) and 50 (18.73%) patients were categorized into non-severe and severe subgroups, respectively. Compared with non-severe patients, severe patients were significantly older (median age, 71.5 years [IQR, 65.8-77.0] vs 43.0 years [IQR, 32.5-57.0]) and more likely to be male (110[50.7%] vs 39[78.0%]). Compared with non-severe cases, more severe cases are smokers (31[62.0%] vs 22[10.1%]). Severe patients were more likely to have coexisting disorders (15[30.0%] vs 26[12.0%]), including overweight or obesity (14[28.0%] vs 16[7.4%]), hypertension (13[26.0%] vs 7[3.2%]), diabetes (12[24.0%] vs 14[6.5%]), respiratory disease (10[20.0%] vs 15[6.9%]). Respiratory rate, heart rate, and mean arterial pressure did not differ markedly between non-severe and severe cases on admission. No significant differences in the exposure history between the two groups were observed (all $p > 0.05$).

Fever and cough were still the most common symptoms in both non-severe (186[85.7%], 155[71.4%]) and severe cases (39[78.0%], 34 [68.0%]). Compared with the non-severe patients, severe patients were more likely to present dyspnea (17[34.0%] vs 26[12.0%]) and confusion (10[20.0%] vs 15 [6.9%]) symptoms. Few

severe patients presented with mild symptoms such as myalgia or arthralgia (37[74.0] vs 99[45.6%]), which should be more noteworthy to avoid delayed or missed diagnosis. The rales and wheezes were more common in severe cases as compared with non-severe cases (21 [42.0%] vs 11[5.1%], 10[20.0%] vs 10[4.6%]). Compared with non-severe patients, most severe patients demonstrated more laboratory abnormalities, including lower level of lymphocytes (46[92.0%] vs 185 [85.3%]), leukocytes (31[62.0%] vs 87[40.1%]), thrombocytes (19[38.0%] vs 42 [19.4%]) and albumin (44[88.0%] vs 19[8.8%]), as well as higher level of D-dimer (13[26.0%] vs 6[2.8%]), C-reactive protein (29 [58.0%] vs 16 [12.5%]), procalcitonin(14[28.0%] vs 10 [9.9%]), lactate dehydrogenase (18[36.0%] vs 39[18.0%]), creatine kinase (18[36.0%] vs 32[14.7%]), myoglobin (7[33.3%] vs 1 [1.8%]) and troponin (3[14.3%] vs 0[0%]). As for lymphocyte subsets, significantly more severe patients had lower level of CD4 positive T cells and CD3 positive T cells (45[100.0%] vs 29[56.9%], 31[68.9%] vs 20[39.2%]). More severe cases had lower level of CD8 positive T cells (20[44.4.0%] vs 13[25.5%], $p=0.051$), while no significant difference was shown. Further comparison the inflammatory cytokines between severe and non-severe patients showed that the level of IL-6, IL-17A and TNF- α was remarkably elevated in severe patients (32[84.2%] vs 15[51.7%], 25[65.8%] vs 10[34.5%], 17[44.7%] vs 5[17.2%]).

Treatment and complications

All patients were treated in isolated wards, among whom critically severe patients were treated in intensive care unit with negative pressure wards. The treatment, complications and outcomes are shown in Table 3. All patients received antiviral therapy (267, 100%), including interferon, opinavir, arbidol, ribavirin. Most non-severe patients received antiviral therapy only for pharmacotherapy. Few non-severe patients (7, 3.2%) with bacterial infection evidence received empirical antibiotic treatments (moxifloxacin and others), while more severe patients received antibiotic treatments (36, 72.0%). 5 severe patients received antifungal therapy (casprofungin) (5, 10.0%). None of non-severe patients received systemic glucocorticoid therapy, while a portion of severe patients (38, 76.0%), without

obvious immune deficiency, received systemic corticosteroid therapy, usually methylprednisolone 40-80mg for 3-5 days. There is only one critically severe patient who received 120mg methylprednisolone. A total of 35 patients (70.0%) received immunopotentiators (thymalfasin 1.6mg/day) or immunoglobulin treatments and 13 severe patients (26.0%) received vasopressors for shock rescue.

Few non-severe patients received ordinary oxygen therapy, delivered by nasal cannula or face mask at 1-4 liters per minute (41, 18.9%). Oxygen therapy including invasive mechanical ventilation, non-invasive mechanical ventilation, high-flow nasal cannula oxygen therapy (HFNC) was adopted only in severe patients with respiratory failure (5[10.0%], 35[70.0%], 12[24.0%]). It is worth noting that 3 critically severe patients received invasive mechanical ventilation in prone position, and the oxygenation improved remarkably. Moreover, traditional Chinese medicine was adopted to most of severe patients (43,86.0%). Currently, none of patients received extracorporeal membrane oxygenation (ECMO) therapy, kidney replacement therapy or convalescent plasma therapy. However, 3 critically severe patients are going to receive ECMO after professional assessment. And, two discharged COVID-19 patients promised to donate convalescent plasma for critically severe patients' further treatment. As compared with non-severe cases, severe cases suffered higher rates of any complications (27[54.0%] vs 8[3.7%]) during hospital admission. The most common complications were ARDS (33, 12.4%), secondary to shock (13, 4.9%) and acute cardiac injury (3, 1.1%), especially more common for severe patients (ARDS, 54.0%; septic shock, 22.0%; acute cardiac injury, 6.0%). Notably, in our study, all of the critically severe cases are complicated with ARDS of different severity, and 4 death cases died of severe ARDS.

Clinical outcomes

By February 16, 2020, the health commission of Chongqing announced that among 551 confirmed COVID-19 patients in Chongqing, 207(37.57%) patients were discharged, 5 patients (0.91%) were died and 339(61.52%) patients were still in

hospital for treatment , lower than that of Hubei province and mainland China including Hubei province (Fig.4). In our study, 103(38.6%) patients had been discharged and 4(1.5%) patients had died, and all other patients were in hospital. The percentages of patients being admitted to the ICU was 19.9%. The median length of hospital of COVID-19 patients is 15 days (IQR, 11.5-16.0), with longer length of hospital of severe patients than that of non-severe patients (20 days [IQR, 17.5-23.25], 14 days [IQR, 11.0-16.0]).

For severe patients, the duration from admission to developing ARDS is only 3 days (IQR, 2.0-5.0), and the 28-mortality of severe patients was 8.0% (4/50), with much higher when complications occurred (14.8%, [4/27]). Notably, the 28-mortality of critically severe patients complicated with severe ARDS is considerably as high as 44.4% (4/9). Therefore, early diagnosis and intensive care of critically severe COVID-19 cases will be considerably essential to reduce complications and mortality.

Discussion

In December 2019, COVID-19 firstly occurred in Wuhan, Hubei Province, China. The disease has rapidly spread from Wuhan to worldwide¹. On January 30, the World Health Organization has declared the COVID-19 outbreak as a public health emergency due to this rapid infection spreads. However, as one of the major cities imported passengers from Wuhan in China⁹, the regional characteristics of COVID-19 in Chongqing municipality were not reported so far. Our presents study, to our knowledge, firstly portrayed the epidemiological, demographic, clinical, radiological, laboratory characteristics, treatment regimens and clinical outcomes of COVID-19 patients in Chongqing municipality, China. And we further compared the numerous differences between severe and non-severe patients in Chongqing municipality. The 28-day mortality of COVID-19 patients from 3 designed hospitals of Chongqing municipality is 1.5%, approximately consistent with the official fatality rate 0.91%, lower than the 28-day mortality of mainland China including Hubei province (2.51% [1770/70548]), reported by national official statistics as for February 16th, 2020

Recently, there are some studies described the cases of hospitalized patients with COVID-19 in Wuhan or worldwide. First study including 41 cases of COVID-19 in Wuhan, in which most patients had a direct history of exposure to Huanan Seafood Wholesale Market of Wuhan, with high mortality rate (6/41, 15%) in this study⁵. An extended descriptive study from 99 cases in the same hospital further revealed the epidemiology and clinical characteristics of the COVID-19 in Wuhan⁶. Another study from 138 hospitalized COVID-19 patients in Wuhan found that 26% of patients received intensive care unit (ICU) care and further compared the differences between severe cases received ICU care with non-severe cases who did not receive ICU care⁷. Two more researches including COVID-19 cases based on the big data from the whole country delineated the clinical and epidemiological characteristics of COVID-19 in nationwide^{8,13}. The clinical courses and outcomes of critically ill COVID-19 patients was recently reported¹⁴.

In our study, the majority critically severe patients are older and male, consistent with gender difference in previous researches^{6,13,14}. The high susceptibility of males is similar to MERS-CoV and SARS-CoV infection^{15,16}. Although, only few of patients in Chongqing are smokers, more severe cases are smokers. Previous study demonstrated that the gene expression of ACE2, receptor of 2019-nCov, is significantly higher in smoker's lung. ACE2 gene is expressed in specific cell types related to smoking history and actively expressed in remodeled AT2 cells of smokers. Thus, smoking history may indicate a poor prognosis due to its different infection paths with non-smokers¹⁷.

Compared with patients who had a definite direct exposure to Huanan seafood market in Wuhan, the epidemics in Chongqing has transmitted to the coexistence of imported cases and local sporadic or clustered cases. As the strong epidemic control in Hubei was implemented, clustered cases or family aggregation cases gradually compose the majority of confirmed cases in Chongqing. Although small part of patients in Chongqing had coexisting chronic disease, relatively less frequent than that of patients in Wuhan⁶, severe patients were more likely to suffer from underlying comorbidities (diabetes, obesity, cardiovascular and cerebrovascular diseases),

resulting in the deficiency in innate and adaptive immunity of these patients. Among the common comorbidities, we found a significant portion of patients in Chongqing suffered from overweight and obesity, which is more common in severe patients. Obesity-induced chronic inflammation status is well documented to contribute to the progress of multiple diseases¹⁸. Large epidemiological studies have shown that BMI was associated with increased risk of acute respiratory distress syndrome (ARDS) and length of hospital stay, which has already been used in lung injury prediction score (LIPS) to help physicians identify at-risk patients for developing ALI¹⁹. Therefore, elderly male patients with a history of smoke and underlying comorbidities are at increased risk of becoming critically severe if they are suffered from COVID-19 infection, which deserves more attention and intensive care treatment.

As the sequence of 2019-nCoV showing 79.0% nucleotide identity with the sequence of SARS-CoV, and 51.8% identity with the sequence of MERS-CoV²⁰, the clinical characteristics of COVID-19 infection bear resemblance to SARS-CoV and MERS-CoV infection. Dominant symptoms at onset of COVID-19 in Chongqing were still fever, dry cough, fatigue, dyspnea, and myalgia or arthralgia is more common in the Chongqing patients. The absence of fever, especially hyperpyrexia, may increase the difficulty to identify and diagnosis COVID-19 in clinical practice if too much attention was given to fever detection only. Moreover, in our study, a significant proportion of patients in Chongqing initially developed with atypical symptoms, such as upper respiratory tract symptoms (eg, nasal congestion and pharyngalgia) and gastrointestinal symptoms (eg, anorexia, diarrhea and nausea), and even had no obvious symptoms, which is inconsistent with previous study reporting upper respiratory tract and intestinal signs and symptoms are rare in Wuhan province⁵. Therefore, the atypical patients and asymptomatic carriers deserves more attention to avoid delayed or missed diagnosis. Moreover, rales and wheezes are scarcely noted when lung auscultation was performed, due to the lack of sputum or mucus, especially for non-severe patients. Further comparison between the severe and non-severe patients found that severe patients are more likely to suffer from dyspnea and confusion symptoms on disease onset, which may suggest severe complications such

as respiratory failure or septic shock, and is of great value of early identification of critically severe cases. The median durations from symptoms onset to laboratory diagnosis and hospital admission were 4 days and 7 days, with obvious longer time for severe cases, which may lead to the poor outcome due to delayed medical interventions. In general, COVID-19 in severe cases progresses rapidly to lethal complications (ARDS, septic shock, acute cardiac injury, refractory metabolic acidosis and so on), even leading to death. Our study demonstrates that the median interval from symptoms onset to ARDS of severe cases was much shorter than that of non-severe cases. It has been demonstrated that poor populations always endured a disproportionate burden of disease and death from infectious diseases like influenza²¹. A great number of death cases in our study were poorly-educated elders with chronic comorbidities, their illness deteriorated rapidly to severe ARDS within several days, presented as suddenly occurred severe hypoxaemia, malignant arrhythmia, cardiac and respiratory arrest, unfortunately death, despite of timely rescue including invasive ventilation and other advanced medical interventions. Therefore, early diagnosis and management of critically severe COVID-19 cases, especially poorly-educated elderly male with chronic comorbidities, should be vigorously advocated.

Regarding to laboratory tests, consistent with most reports, peripheral lymphocytopenia is the most crucial and common feature for COVID-19 infection. In our study, most patients suffered from varying degrees of lymphocytopenia, especially for critically severe patients. Lymphocytopenia is also a prominent feature for patients with SARS-CoV, H1N1, MERS-CoV virus infection²²⁻²⁵. Progressive lymphopenia is reported to occurred early in the course of SARS and reached its lowest point in the second week in most patients, then, lymphocytes count commonly recovered in the third week²⁵. In terms of lymphocyte subsets, the counts of total T cells, CD4 positive and CD8 positive T cells had reduced in COVID-19 patients on admission. Counts of total T cells and CD3 positive T cells were significantly lower among severe patients, accompanied by an obvious declining tendency in CD8 positive T cells, indicating an adverse outcome. Pathological findings from the biopsy of COVID-19 death patient implied that overactivation of T cells, manifested by increase of highly

proinflammatory Th17 and cytotoxic CD8 T cells, partially accounts for the severe immune injury in death patient²⁶. The phenomenon that T cell counts reduced and functionally exhausted has been reported in previous study, which indicates high risk for further deterioration of COVID-19²⁷. In our study, a progressive decline of lymphocytes and CD4 positive T cells was observed during the deterioration of illness. Thus, the dynamic profile of lymphocytes and lymphocyte subsets are of great value for disease progression and outcomes prediction. Early studies have shown that 2019-nCoV infection increased the release of both inflammatory and anti-inflammatory cytokines from T-helper-1 (Th1) and T-helper-2(Th2) cells, differing from SARS or MERS-infection induced proinflammatory cytokines secretion^{28,29}. Our study demonstrated that pro-inflammatory cytokines IL-6, IL-17A were elevated in mostly patients, with significant higher level of IL-6, IL-17A and TNF- α in severe patients, indicating an underlying relationship between pulmonary inflammation and lung damage in 2019-nCoV patients. So far, the cytokines storm's effects on viral pneumonia are considerable complex and their clinical roles in severe lung injury have not been extensively documented, therefore, further investigations are needed to elucidate immune and inflammation response in 2019-nCoV pathogenesis, which is of crucial importance for efficient treatments. Few of patients presented as elevated levels of infectious parameters, but other abnormalities were less common. While, severe patients obviously manifested more prominent abnormalities, suggesting multiple organ dysfunction and poor outcomes. Additionally, severe cases suffered from lower albumin and hemoglobin, suggesting the importance of nutrition supportive treatments. As for radiologic presentations, more attention should be paid to the cases without obvious radiological abnormalities on admission, so as to avoid the miss or delayed diagnosis. Therefore, it is crucial important to take symptoms, laboratory findings, radiologic findings into account to make an integrated and thorough judgment. The MuLBSTA score, an efficient early warning model for predicting mortality in viral pneumonia³⁰, needs further validation in the future practice.

Currently, no specific treatment available has been advocated for coronavirus infection. As most of patients in Chongqing were non-severe, antiviral therapy was commonly adopted among these patients. Empirical antibiotic therapy was merely administered to few patients with bacterial infection evidence, and ordinary oxygen therapy was supplied only if hypoxemia occurred. As for the severe cases, comprehensive treatment is important. Mechanical ventilation is the main respiratory supportive treatment for critically ill patients, which should be administered as soon as possible if the normal oxygenation cannot maintain. Treatments were focused on supportive therapy, which focuses on limiting further lung damages through a combination of lung-protective ventilation to prevent ventilator-associated lung injury and conservative fluid therapy to prevent the hyperpermeability of alveolar endothelial and epithelial barriers and promote lung edema resorption. Although, systematic corticosteroid treatment is not routinely recommended for COVID-19 patients³¹, while based on the pathological findings of COVID-19 biopsy that pulmonary edema and hyaline membrane formation²⁶, low dosage of intravenous methylprednisolone (usually 20-80mg for 3-5 days) was still provided to some severe patients at early stage of the illness to suppress lung inflammation and hasten radiographic improvement. Immunopotentiator and γ -immunoglobulin should be administered to enhance immune responses and pathogen clearance based on the patient's condition. Notably, traditional Chinese medicine formulae was extensively utilized in critically severe patients after precise and professional evaluation. Two discharged COVID-19 patients promised to donate convalescent plasma for critically severe patients' further treatment. Previous Meta-Analysis reported that patients with H5N1 influenza pneumonia who received influenza-convalescent human blood products may have experienced a reduction in the risk for death³². Convalescent plasma may reduce the mortality of SARS coronavirus and severe influenza infection³³. On the contrary, high-titre anti-influenza plasma was reported to confer no significant benefit over non-immune plasma for treating patients with severe influenza A³⁴. Transfusion of convalescent plasma into 84 patients with Ebola virus disease was

not associated with a significant improvement in survival³⁵. Therefore, it is still too early to judge the efficiency of these therapy, much more studies are still needed

In summary, our study firstly demonstrated the regional disparity of COVID-19 in Chongqing and further thoroughly compared the differences between severe and non-severe patients in Chongqing municipality, China. The 28-day mortality of COVID-19 patients from 3 designed hospitals of Chongqing municipality is 1.5%, approximately consistent with the official fatality rate 0.91%, lower than that of Hubei province and mainland China including Hubei province. Early isolation, early diagnosis, early management, combined with the strong epidemic control in Hubei and the effective prevention of local cluster outside Hubei might collectively contribute to the marked reduced 28 day-mortality in Chongqing municipality. However, for severe patients, the 28-mortality was relatively high, with much higher when complications occurred. Notably, the 28-mortality of critically severe patients complicated with severe ARDS is considerably as high as 44.4%. Thus, early diagnosis and intensive care of critically severe COVID-19 cases, especially those combined with ARDS, will be considerably essential to reduce mortality.

Acknowledgements

Daoxin Wang, Jin Tong, Jianglin Xiang designed the research; Di Qi, Xiaofeng Yan, Xumao Tang, Junnan Peng, Longhua Feng, Guodan Yuan, An Zhang, Yaokai Chen, Jing Yuan, Xia Huang, Xianxiang Zhang, Peng Hu, Yuyan Song, Chunfang Qian, Qiangzhong Sun collected the data; Di Qi, Xumao Tang, Junnan Peng, Qian Yu performed data analysis; Di Qi, Xiaofeng Yan performed manuscript writing; Di Qi, Xumao Tang, Junnan Peng, Qian Yu contributed to study advice. Daoxin Wang, Jin Tong, Jianglin Xiang directed the study and participated in the review. Di Qi, Xiaofeng Yan, Xumao Tang contributed equally.

Ethics

This research was approved by the institutional ethics board of the Second Affiliated Hospital of Chongqing Medical University (No.2020-09), Chongqing public health

medical center (No.2020-015-01-KY), Chongqing three gorges central hospital (No.2020-13) and Qianjiang central hospital of Chongqing (No.2020-07).

Grants

This study was supported by National Natural Science Foundation of China (Grant NO. 81670071) and the National Natural Science Foundation for Young Scholars of China (Grant NO. 81800083).

Reference

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *Journal of medical virology*. 2020;92(4):401-402.
2. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chinese medical journal*. 2020.
3. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *The New England journal of medicine*. 2020.
4. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nature Reviews Microbiology*.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020;395(10223):507-513.
7. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
8. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel

- coronavirus infection in China. *medRxiv*. 2020:2020.2002.2006.20020974.
9. Zhao S, Zhuang Z, Ran J, et al. The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: A data-driven correlational report. *Travel medicine and infectious disease*. 2020;33:101568.
 10. <WHO clinical-management-of-novel-cov.pdf>.
 11. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. *Jama*. 2012;307(23):2526-2533.
 12. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Military Medical Research*. 2020;7(1):4.
 13. Yang Y, Lu Q, Liu M, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. *medRxiv*. 2020:2020.2002.2010.20021675.
 14. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*.
 15. Badawi A, Ryoo SG. Prevalence of Comorbidities in the Middle East Respiratory Syndrome Coronavirus (MERS-CoV): A Systematic Review and Meta-analysis. *International Journal of Infectious Diseases*. 2016;49(C):129-133.
 16. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *Journal of immunology (Baltimore, Md. : 1950)*. 2017;198(10):4046-4053.
 17. Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. *medRxiv*. 2020:2020.2002.2005.20020107.
 18. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism.

- Journal of atherosclerosis and thrombosis*. 2011;18(8):629-639.
19. Trillo-Alvarez C, Cartin-Ceba R, Kor DJ, et al. Acute lung injury prediction score: derivation and validation in a population-based sample. *European Respiratory Journal*.37(3):604-609.
 20. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet (London, England)*. 2020;395(10224):565-574.
 21. Ferguson N. Poverty, death, and a future influenza pandemic. *Lancet (London, England)*. 2006;368(9554):2187-2188.
 22. Cao B, Li X-W, Mao Y, et al. Clinical Features of the Initial Cases of 2009 Pandemic Influenza A (H1N1) Virus Infection in China. *The New England journal of medicine*.361(26):2507-2517.
 23. Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *The Lancet. Infectious diseases*. 2013;13(9):752-761.
 24. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. *The Journal of experimental medicine*. 2005;202(3):415-424.
 25. Wong, M RS. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. *Bmj British Medical Journal*.326(7403):1358-1362.
 26. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*. 2020.
 27. Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). *medRxiv*. 2020:2020.2002.2018.20024364.
 28. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clinical and experimental immunology*. 2004;136(1):95-103.

29. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine*. 2018;104:8-13.
30. Guo L, Wei D, Zhang X, et al. Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score. *Frontiers in microbiology*. 2019;10:2752.
31. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet (London, England)*. 2020;395(10223):473-475.
32. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Annals of internal medicine*. 2006;145(8):599-609.
33. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *The Journal of infectious diseases*. 2015;211(1):80-90.
34. Beigel JH, Aga E, Elie-Turenne MC, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. *The Lancet. Respiratory medicine*. 2019;7(11):941-950.
35. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. *The New England journal of medicine*. 2016;374(1):33-42.

Table 1. Epidemiological and clinical characteristics of COVID-19 patients in Chongqing

Clinical characteristics, symptoms or signs	Disease severity			
	All patients (n=267)	Non-severe (n=217)	Severe (n=50)	P value
Age, Median (range) – yrs	48.0(20-80)	43.0(20-79)	71.5(39-80)	
Age, Median (IQR) – yrs	48.0(35.0-65.0)	43.0(32.5-57.0)	71.5(65.8-77.0)	< 0.001
Age groups – No. %				
< 50 yrs	138(51.7)	136(62.7)	2(4.0)	< 0.001
≥ 50 yrs	129(48.3)	81(37.3)	48(96.0)	-
Male sex – No.,%	149(55.8)	110(50.7)	39(78.0)	< 0.001
Smoking history – No., %				
smokers	53(19.9)	22(10.1)	31(62.0)	< 0.001
Non-smokers	214(80.1)	195(89.9)	19(38.0)	-
Comorbidities – No., %				
Any	41(15.4)	26(12.0)	15(30.0)	0.001
Overweight or obesity	30(11.2)	16(7.4)	14(28.0)	< 0.001
Diabetes	26(9.7)	14(6.5)	12(24.0)	< 0.001
Hypertension	20(7.5)	7(3.2)	13(26.0)	< 0.001
Respiratory system disease	25(9.4)	15(6.9)	10(20.0)	0.009
Cardiovascular and cerebrovascular diseases	13(4.9)	9(4.1)	4(8.0)	0.437
Exposure to source of transmission within 14 days – No.,%				
a recent travel to Wuhan or Hubei province	41(15.4)	30(13.8)	11(22.0)	0.148
contact with patients from Wuhan or Hubei	139(52.1)	113(52.1)	26(52.0)	0.992
contact with the patients infected by confirmed patients from Wuhan.	18(6.7)	16(7.4)	2(4.0)	0.540
No definite epidemiological link	69(25.8)	58(26.7)	11(22.0)	0.592
Symptoms and signs				
Respiratory symptoms – No., %				
Fever on admission	225(84.3)	186(85.7)	39(78.0)	0.197
Temperature on admission (°C)	37.6(36.1-40.4)	37.6(36.1-40.4)	37.5(36.5-40.2)	0.205
37.3-38.0	181(67.8)	151(69.6)	30(60.0)	0.191

> 38.0	44(16.5)	35(16.1)	9(18.0)	0.748
myalgia or arthralgia	136(50.9)	99(45.6)	37(74.0)	< 0.001
Cough	189(70.8)	155(71.4)	34(68.0)	0.631
Fatigue	208(77.9)	170(78.3)	38(76.0)	0.719
Chill	30(11.2)	19(8.8)	11(22.0)	0.008
Nasal congestion	53(19.9)	44(20.3)	9(18.0)	0.716
pharyngalgia	41(15.4)	33(15.2)	8(16.0)	0.889
Hemoptysis	5(1.9)	3(1.4)	2(4.0)	0.236
Dyspnea	43(16.1)	26(12.0)	17(34.0)	< 0.001
confusion	25(9.4)	15(6.9)	10(20.0)	0.009
Nausea or vomiting	6(2.2)	5(2.3)	1(2.0)	1.000
Diarrhea	10(3.7)	7(3.2)	3(6.0)	0.604
anorexia	46(17.2)	33(15.2)	13(26.0)	0.094
Signs – No., %				
Throat congestion	6(2.2)	4(1.8)	2(4.0)	0.690
Tonsil swelling	3(1.1)	2(0.9)	1(2.0)	0.465
Enlargement of lymph nodes	3(1.1)	2(0.9)	1(2.0)	0.465
rales	32(12.0)	11(5.1)	21 (42.0)	< 0.001
wheezes	20(7.5)	10(4.6)	10(20.0)	0.001
Onset of symptom to, median (IQR), d				
diagnosis	4(2.0-8.0)	4(2.0-7.0)	7(3.0-11.7 5)	< 0.001
Hospital admission	7(3.0-10.0)	6(3.0-9.0)	9(6.0-12.7 5)	< 0.001

Table 2. Laboratory and radiographic and findings of COVID-19 patients in Chongqing

Radiologic and laboratory findings	All patients (n=267)	Disease severity		
		Non-severe (n=217)	Severe (n=50)	P value
Laboratory findings				
PaO₂: FiO₂, median (IQR)	310(151-409)	353(302-409)	239(151-300)	< 0.001
Blood leukocyte count– No., %				
>9.5 * 10 ⁹ /L	15(5.6)	11(5.1)	4(8.0)	0.638
3.5-9.5 ⁹ /L	134(50.2)	119(54.8)	15(30.0)	0.002
<3.5 * 10 ⁹ /L	118(44.2)	87(40.1)	31(62.0)	0.005
Neutrophils count– No., %				
>6.3* 10 ⁹ /L	31(11.6)	21(9.7)	10(20.0)	0.040
1.8-6.3 ⁹ /L	146(54.7)	125(57.6)	21(42.0)	0.046
<1.8 * 10 ⁹ /L	90(33.7)	71(32.7)	19(38.0)	0.476
Lymphocyte count– No., %				
< 1.31 * 10 ⁹ /L	231(86.5)	185(85.3)	46(92.0)	0.208
Lymphocyte subsets				
CD3<770 cells/μL – No./total No. (%)	51/96(53.1)	20/51(39.2)	31/45(68.9)	0.004
CD4<414 cells/μL – No./total No. (%)	74/96(77.1)	29/51(56.9)	45/45(100.0)	< 0.001
CD8<238 cells/μL – No./total No. (%)	33/96(34.4)	13/51(25.5)	20/45(44.4)	0.051
Platelet count– No., %				
<140 * 10 ⁹ /L	61(22.8)	42(19.4)	19(38.0)	0.005
Haemoglobin level – g/dl	135(95-165)	135(109-165)	125(95-155)	< 0.001
C-reactive protein level ≥10 mg/liter – No./total No. (%)	45/178(25.3)	16/128(12.5)	29/50(58.0)	< 0.001
Procalcitonin level ≥0.5 ng/ml – No./total No. (%)	24/151(15.9)	10/101(9.9)	14/50(28.0)	0.004
Erythrocyte sedimentation rate ≥10 mm/h – No./total No. (%)	44/106(41.5)	19/65(29.2)	25/41(61.0)	0.001
TNF-α≥2.31 pg/ml – No./total No. (%)	22/67(32.8)	5/29(17.2)	17/38(44.7)	0.018
IL-10≥4.91 pg/ml – No./total No. (%)	12/67(17.9)	4/29(13.8)	8/38(21.0)	0.443
IL-6≥5.3 pg/ml – No./total No. (%)	47/67(70.1)	15/29(51.7)	32/38(84.2)	0.004
IL-4≥2.8 pg/ml – No./total No. (%)	4/67(6.0)	2/29(6.9)	2/38(5.3)	1.000
IL-2≥5.71 pg/ml – No./total No. (%)	5/67(7.5)	2/29(6.9)	3/38(7.9)	1.000
IL-17A≥20.6 pg/ml – No./total No. (%)	35/67(52.2)	10/29(34.5)	25/38(65.8)	0.011
IFN-γ≥7.42 ng/ml – No./total No. (%)	11/67(16.4)	6/29(20.7)	5/38(13.2)	0.623

Lactose dehydrogenase ≥ 245 U/l – No., %	57(21.3)	39(18.0)	18(36.0)	0.005
Creatine kinase ≥ 170 U/l– No., %	50(18.7)	32(14.7)	18(36.0)	0.001
Creatine Kinase Isoenzyme ≥ 25 U/l– No., %	33(12.4)	20(9.2)	13(26.0)	0.001
Myoglobin > 58 ng/ml – No./total No. (%)	8/76(10.5)	1/55(1.8)	7/21(33.3)	< 0.001
Troponin T > 14 pg/ml – No./total No. (%)	3/76(3.9)	0/55(0)	3/21(14.3)	0.019
Aspartate aminotransferase > 35 U/l– No., %	19(7.1)	9(4.1)	10(20.0)	< 0.001
Alanine aminotransferase > 40 U/l – No., %	20(7.5)	10(4.6)	10(20.0)	0.001
Albumin < 40 g/l – No., %	63(23.6)	19(8.8)	44(88.0)	< 0.001
Total bilirubin ≥ 26 μmol/l– No., %	6(2.2)	3(1.4)	3(6.0)	0.082
Direct Bilirubin ≥ 8.6 μmol/l– No., %	7(2.6)	4(1.8)	3(6.0)	0.243
Indirect Bilirubin ≥ 16 μmol/l – No., %	3(1.1)	2(0.9)	1(2.0)	0.465
Creatinine ≥ 106 μmol/l– No., %	4(1.5)	1(0.5)	3(6.0)	0.022
D-dimer ≥ 0.5 mg/l – No., %	19(7.1)	6(2.8)	13(26.0)	< 0.001
Radiologic findings – No./total No. (%)				
bilateral ground-glass opacity or patchy shadowing	100/231(43.3)	55/181(30.4)	45/50(90.0)	< 0.001
unilateral ground-glass opacity or patchy shadowing	95/231(41.1)	90/181(49.7)	5/50(10.0)	< 0.001
consolidation or fibrous stripes-like shadows	13/231(5.6)	4/181 (2.2)	9/50 (18.0)	< 0.001
pneumothorax	1/231(0.4)	0/181	1/50 (2.0)	0.216
hydrothorax	1/231(0.4)	0/181	1/50 (2.0)	0.216
no radiological abnormality	36/231(15.6)	36/181(19.9)	0	0.001

Table 3. Complications, treatment and outcomes of COVID-19 patients in Chongqing

Characteristics	All patients (n=267)	Disease severity		P value
		Non-severe (n=217)	Severe (n=50)	
Complications – No., %	35(13.1)	8(3.7)	27 (54.0)	<0.001
Acute respiratory distress syndrome	33(12.4)	6(2.8)	27(54.0)	<
mild	14(42.4)	4(66.7)	10(37.0)	0.363
moderate	10(30.3)	2(33.3)	8(29.6)	1.000
severe	9(27.3)	0(0.0)	9(33.3)	0.156
Septic shock	13(4.9)	2(0.9)	11(22.0)	<
Acute cardiac injury	3(1.1)	0 (0.0)	3(6.0)	0.006
Disseminated intravascular coagulation	1(0.4)	0	1(2.0)	0.187
Time from admission to developing ARDS (days)				
Median, interquartile range	4.0(2.0-5.0)	7.5(6.5-8.75)	3.0(2.0-5.0)	0.003
Range	1.0-11.0	5.0-11.0	1.0-7.0	
Antiviral treatments – No., %	267(100.0)	217(100.0)	50(100.0)	
Empirical antibiotic treatments – No., %	43(16.1)	7(3.2)	36 (72.0)	<
Antifungal treatments– No., %	5(1.9)	0(0.0)	5(10.0)	<
Systemic corticosteroids treatments – No., %	38(14.2)	0(0.0)	38(76.0)	<
Immunopotentiators or immunoglobulin treatments – No., %	35(13.1)	0(0.0)	35(70.0)	<
Vasopressors treatment – No., %	13(4.9)	0(0.0)	13(26.0)	<
Ordinary oxygen therapy – No., %	91(34.1)	41(18.9)	50(100.0)	<
Mechanical ventilation – No., %				<

Invasive	5(1.9)	0(0.0)	5(10.0)	<	0.001
Non-invasive	35(13.1)	0(0.0)	35(70.0)	<	0.001
high-flow nasal cannula oxygen therapy	12(4.5)	0(0.0)	12(24.0)	<	0.001
Use of extracorporeal membrane oxygenation – No., %	0(0.0)	0(0.0)	0(0.0)		
Use of continuous renal replacement therapy – No., %	0(0.0)	0(0.0)	0(0.0)		
Use of traditional Chinese medicine – No., %	55(20.6)	12(5.5)	43(86.0)	<	0.001
Intensive care unit admission – No., %	53(19.9)	8(3.7)	45(90.0)	<	0.001
Clinical outcomes					
Recovered and discharge	103(38.6)	97(44.7)	6(12.0)	<	0.001
Death	4(1.5)	0(0.0)	4(8.0)		0.001
Staying in hospital	160(59.9)	120(55.3)	40(80.0)		0.001
Time from admission to discharge (days)					
Median, interquartile range	15(11.5-16)	14(11-16)	20(17.5-23.25)		0.001
Range	(9-25)	(9-16)	(14-25)		




Fig.1 Chest computed tomography of a 56 years old female patient of non-sever COVID-19 in Chongqing on admission.




Fig.2 Chest computed tomography of a 65 years old female patient of severe COVID-19 in Chongqing on admission.




Fig.3 Chest computed tomography of a 39 years old male patient of severe COVID-19 in Chongqing on admission.




Fig.4 Comparison of 28-day mortality among Hubei province, mainland China including Hubei province, mainland China excluding Hubei province and Chongqing municipality.